Commentary: Evaluating potential glioma serum biomarkers, with future applications

Michael Goutnik, Brandon Lucke-Wold

Abstract
Systemic inflammation within malignant glioma is a topic of ongoing significance. In this commentary, we highlight recent findings from Gandhi et al and discuss alternative approaches. We present a counter argument with findings that IL-6 markers are controversial. We highlight the potential benefit of looking at microRNAs and other biomarkers. Finally, we present ideas for future application involving differentiation between radiation necrosis and recurrence. The commentary is intended to serve as a catalyst for further scientific discovery.

Key Words: Systemic inflammation; Malignant glioma; Neutrophil-lymphocyte ratio; Interleukin-6

Core Tip: Systemic inflammation in malignant glioma, along with the potential for blood-based biomarkers, is an exciting field of ongoing research. We have discussed supporting and contrasting evidence for glioma blood-based biomarkers, along with future research proposals.
non-invasive panel consisting of four inflammatory markers to distinguish between histological grades of glioma and IDH-mutant/wildtype glioma, as well as predicting overall survival. The premise behind the potential effectiveness of such a panel is the chronic inflammatory state that results from various stimuli like tumor antigens and oncogenes that promote abnormal growth and leakage of markers into the peripheral circulation. The inflammatory environment of gliomas is not a new finding, as Morimura et al. [2] previously found. 20%-30% of cells in glioma samples were recognizable by various macrophage/microglia markers and that tumor proliferation correlates with macrophage infiltration [2]. Parney et al. [3] similarly demonstrated the infiltration of gliomas by macrophages. However, there is conflicting evidence as to whether these infiltrating macrophages are capable of secreting cytokines and promoting an effective immune response [4,5].

Nonetheless, other studies have found similar results with respect to the markers that Gandhi et al. [1] focused upon within their paper. For example, Adams et al. [6] found the kynurenine pathway to be significantly activated in plasma samples from glioblastoma (GBM) patients, an effect that is hypothesized to inhibit anti-tumor immunity by depleting tryptophan from the tumor microenvironment and thus suppressing T-cell proliferation. Du et al. [7] also demonstrated that the serum Kyn/Trp ratio in patients with high grade gliomas was significantly higher than in those with lower grade gliomas. Similarly, Juhasz et al. [8] used dynamic PET imaging of patients with gliomas to demonstrate shunting of tryptophan (Trp) toward kynurenine (Kyn) metabolism. Mitsuka et al. [9] evaluated the expression of indoleamine 2,3-dioxygenase (IDO), an important enzyme in tryptophan metabolism that yields catabolites including kynurenine, in 75 surgical specimens including diffuse astrocytomas, anaplastic astrocytomas, and GBMs. The authors found IDO expression correlated with glioma grade, expression increased in secondary glioblastoma relative to the initial lower-grade glioma, and stronger expression was associated with worse survival in GBM patients [9]. Zhai et al. [10] also found GBM patients with high kynurenine/tryptophan ratios to have worse survival compared to those with lower values. However, no other studies were found that replicated Gandhi et al. [1]'s findings of tryptophan metabolites distinguishing between IDH-wildtype and mutant gliomas.

The neutrophil-lymphocyte ratio was another significant marker in Gandhi et al. [1]'s study, which has been shown to be effective in distinguishing between different grades of glioma and predicting overall survival and progression-free survival in a variety of gliomas [11-19]. Concurrent with Gandhi et al. [1]'s results, NLR has also been shown to distinguish between IDH-mutant and wildtype gliomas, with mutant IDH1 gliomas featuring lower levels of NLR [17]. Furthermore, telomerase activity has also been associated with glioma grade and overall survival, which Gandhi et al. [22] also demonstrated [20-22]. However, IDH mutant cell lines appear to indirectly reactivate hTERT, which contrasts with Gandhi et al. [22]'s finding of higher hTERT in IDH-wildtype tumors [23].

Gandhi et al. [1] highlighted positive correlations between median marker values and tumor grade, as well as significantly higher molecular marker values for IDH-wildtype compared to IDH-mutant gliomas. Furthermore, they found that IL-6 had a strong correlation with tumor grade, which has been replicated by immunohistochemistry, gene expression studies and CSF and serum analysis [24,25]. Some of these findings have been challenged in the literature, however. Cytokines interact with receptors, antibodies, binding proteins, and also often have short half-lives, so total concentrations may not reflect production and/or secretion levels [26]. Samaras et al. [26] thus used the ELISPOT method (a cell-based cytokine measuring system) to demonstrate greater IL-6 secretion from peripheral monocytes and greater IL-10 secretion from peripheral mononuclear and tumor cells in glioma patients compared to controls. However, there was only a marginal increase in significance in median IL-6 secretion between glioma grades, but this may be due to small sample size [26]. Holst et al. [27] studied 158 patients and found no difference in serum IL-6 between GBM and lower grade gliomas once age was accounted for, and that IL-6 was significant for worse survival only in univariate analysis. However, Holst et al. [27] and Jiang et al. [28] did find IL6 RNA expression to differ between IDH-mutant and wild type gliomas, which parallels the finding of Gandhi et al. [1]. Other studies have not found a relationship between IL-6 Levels and survival in GBM [29,30]. In one study involving 38 glioma patients, serum IL-6 decreased in glioma patients and inversely correlated with grade, while serum IL-17A was specific to gliomas (compared to meningiomas and schwannomas) and positively correlated with grade [31]. However, serum IL-6 has been associated with a negative prognosis in other cancers [32].

Divergent results regarding IL-6 may reflect confounding bias and/or differential treatment, as corticosteroid treatment may decrease plasma IL-6 [27,33]. Similarly, brain surgery may increase serum inflammatory markers, suggesting that these proteins reflect brain injury and disruption of the blood-brain barrier rather than tumor burden [34]. There may also be false positives in patients with other inflammatory or malignant processes [12]. Furthermore, there are a variety of other circulating biomarkers that may influence survival, such as circulating tumor cells and microRNAs [35,36]. In addition, other non-serum based noninvasive biomarkers like urinary 2-hydroxyglutarate (2-HG), a product of mutant IDH acting on α-ketoglutarate, may distinguish between IDH-mutant and IDH-wild type glioma [37,38]. This metabolite may also be detected by magnetic resonance spectroscopy, and correlates with IDH mutation status [39]. Nonetheless, Gandhi et al. [1]'s panel is promising with a 94.4% sensitivity and 96.7% specificity, suggesting potential therapeutic targets. More prospective work with larger cohorts is needed to evaluate the efficacy of Gandhi et al. [1]'s proposed immune marker panel in predicting tumor grade and survival, and whether adding, removing, and/or combining other
circulating and non-circulating biomarkers may be more effective in terms of accuracy and cost. An interesting application of Gandhi et al.’s work would involve testing the ability of their panel to differentiate tumor progression from radiation necrosis[40]. Inflammation, including the pro-inflammatory IL-6 cytokine, likely contributes to the pathophysiology of radiation necrosis[41,42]. It is feasible that a different set of thresholds for the four molecular markers, or the inclusion of other markers like miR-21[43], predicts radiation necrosis compared to tumor progression. Furthermore, a different choice of patient controls could be useful in further evaluating the panel’s specificity. Instead of forty-five healthy controls without a history of inflammation or autoimmune disease, patients with non-glial brain tumors and/or other inflammatory conditions may serve as controls.

Further testing of the panel may include other potentially important molecules like IL-33. IL-33 has been shown to induce a pro-inflammatory environment within gliomas and inversely correlates with survival[44-46]. De Boeck et al.[44] also demonstrated IL-33 induced upregulation of inflammatory gene expression, including IL-6, and proposed that IL-33 secretion from glioma cells recruits monocytes from the circulation. Thus, IL-33 may be more specific to glioma than Gandhi et al.’s markers, and may also be sufficient alone as a marker. Differentiating the markers that distinguish high grade versus low grade gliomas early will be valuable and can be validated in preclinical studies.

FOOTNOTES

Author contributions: Goutnik M wrote the manuscript; Lucke-Wold B contributed to writing, and edited the manuscript.

Conflict-of-interest statement: The authors deny any conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United States

ORCID number: Michael Goutnik 0000-0002-3720-2330; Brandon Lucke-Wold 0000-0001-6577-4080.

S-Editor: Liu JH
L-Editor: A
P-Editor: Liu JH

REFERENCES

1 Gandhi P, Shrivastava R, Garg N, Sorte SK. Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients. World J Clin Oncol 2021; 12: 947-959 [PMID: 34733616 DOI: 10.5306/wjco.v12.i10.947]
2 Morimura T, Neuchrist C, Kitz K, Budka H, Scheiner O, Kraft D, Lassmann H. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol 1990; 80: 287-294 [PMID: 2399810 DOI: 10.1007/BF00294647]
3 Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 2009; 110: 572-582 [PMID: 19199469 DOI: 10.3171/2008.7.JNS08475]
4 Hussain SF, Yang D, Sukli D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8: 261-279 [PMID: 16775224 DOI: 10.1215/15280418-2006-008]
5 Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2011; 59: 1169-1180 [PMID: 21446047 DOI: 10.1002/glia.21136]
6 Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, Sundaram G, Braidy N, Brew BJ, Guillemijn GJ. Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One 2014; 9: e112945 [PMID: 25415278 DOI: 10.1371/journal.pone.0112945]
7 Du L, Xing Z, Tao B, Li T, Yang D, Li W, Zheng Y, Kuang C, Yang Q. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct Target Ther 2020; 5: 10 [PMID: 32296044 DOI: 10.1038/s41392-019-0103-4]
8 Juhász C, Chugani DC, Barger GR, Kupsky WJ, Chakraborty PK, Muzik O, Mittal S. Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity. Clin Nucl Med 2012; 37: 838-842 [PMID: 22889771 DOI: 10.1097/RLU.0b013e318251e458]
9 Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013; 72: 1031-8; discussion 1038 [PMID: 23426156 DOI: 10.1227/NEU.0b013e31828c9495]
10 Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas MK, Redamaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT, Bloch O, Wainwright DA. The kynurenic to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci 2015; 22: 1964-1968 [PMID: 26279502 DOI: 10.1016/j.jocn.2015.06.018]

11 Wang PF, Meng Z, Song HW, Yao K, Duan ZJ, Yu CJ, Li SW, Yan CX. Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival. Front Pharmacol 2018; 9: 886 [PMID: 30154718 DOI: 10.3389/fphar.2018.00886]

12 Zheng SH, Huang Jl, Chen M, Wang BL, Ou QS, Huang SY. Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study. J Neurosurg 2018; 129: 583-592 [PMID: 29099300 DOI: 10.3171/2017.3.JNS161648]

13 Lei YY, Li YT, Hu QL, Wang J, Sui AX. Prognostic impact of neutrophil-to-lymphocyte ratio in glomas: a systematic review and meta-analysis. World J Surg Oncol 2019; 17: 152 [PMID: 31472673 DOI: 10.1186/s12957-019-1866-5]

14 Weng W, Chen X, Gong S, Guo L, Zhang X. Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioma survival. Neurocancer J 2018; 40: 917-922 [PMID: 30074469 DOI: 10.1008/s11061-012-14972-1]

15 Gomes Dos Santos A, de Carvalho RF, de Moraes ANLR, Silva TM, Baylão VMR, Azevedo M, de Oliveira AJM. Role of neutrophil-to-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. Crit Rev Oncol Hematol 2021; 163: 103372 [DOI: 10.1016/j.critrevonc.2021.103372]

16 Clavreul A, Lemée JM, Soulard G, Rousseau A, Mene P. A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide. Cancers (Basel) 2021; 13 [PMID: 34830935 DOI: 10.3390/cancers13225778]

17 Auezoa R, Ivanova N, Akshulakov S, Zheplisheva B, Kozhakhmetova N, Ryskeldiev N, Mustafin K, Teltayev D, Auezoa L. Structural dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. Cancer Manag Res 2019; 11: 3227-3236 [PMID: 31114362 DOI: 10.2147/CAMR.S195754]

18 Gan Y, Zhou X, Niu X, Li J, Wang T, Zhang H, Yang Y, Liu Y, Mao Q. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas. World Neurosurg 2019; 127: e261-e267 [PMID: 30898756 DOI: 10.1016/j.wneu.2019.03.085]

19 Tan Z, Shen L, Wu H, Deng L, Li Z, Huang X. Preoperative Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Biomarker in Patients with Low-Grade Gliomas. World Neurosurg 2019; 132: e585-e590 [PMID: 31442620 DOI: 10.1016/j.wneu.2019.08.068]

20 Huang F, Kanno H, Yamamoto I, Lin Y, Kubota Y. Correlation of clinical features and telomerase activity in human gliomas. Neurooncol 1999; 43: 137-142 [PMID: 10537252 DOI: 10.1038/100658817785]

21 Dorriss K, Sobo M, Oman-Thomas A, Panditharattna E, Stevenson CB, Gardner SL, Dewire MD, Pierson CR, Olsheski R, Rempel SA, Goldman S, Miles L, Fouliad M, Drissi R. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. J Neurooncol 2014; 117: 67-76 [PMID: 24477622 DOI: 10.1007/s11060-014-1374-9]

22 Gandi P, Khare R, Garg N. Evaluating the potential of circulating hTERT levels in glioma: can plasma levels serve as an independent prognostic marker? J Neurooncol 2017; 135: 255-261 [PMID: 28756592 DOI: 10.1007/s11060-017-2587-6]

23 Obba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JP, Ronen SM, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res 2016; 76: 6608-6689 [PMID: 27578882 DOI: 10.1158/0008-5472.CAN-16-0696]

24 Rohlik C, Renault-Llorca F, Kényény JL, Lemaire JJ, Jullien C, Cabit-Bouvier C, Finat-Duclos F, Verrelle P. Interleukin-6 overexpression is a marker of malignancy in human gliomas. J Neurosurg 2001; 94: 97-101 [PMID: 11147905 DOI: 10.3171/jns.2001.94.1.0097]

25 Shan Y, He X, Song W, Han D, Niu J, Wang J. Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med 2015; 8: 9114-9120 [PMID: 26395566]

26 Samaras V, Pipiri C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS, Boviatsis EI, Sakas DE, Lea RW, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS, Boviatsis EI, Sakas DE, Lea RW. Reflections on the role of IL-6 in glioma growth and progression. World Neurosurg 2013; 79: 415-424 [PMID: 23582587 DOI: 10.1016/j.wneu.2012.06.048]

27 Holst CB, Christensen JJ, Skjøth-Rasmussen J, Hammerlik P, Poulsen HS, Johansen JS. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Front Oncol 2020; 10: 478 [PMID: 32363159 DOI: 10.3389/fonc.2020.00478]

28 Jiang Y, Han S, Cheng W, Wang Z, Wu A. NFAT1-regulated IL-6 signalling contributes to aggressive phenotypes of glioma. Cell Commun Signal 2017; 15: 54 [PMID: 28958522 DOI: 10.1186/s12964-017-0210-1]

29 Chioren R, Berindan-Neagoe I, Braicu C, Florian IS, Leucuta D, Crisan D, Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data. Cancer Biomark 2014; 14: 185-194 [PMID: 24878020 DOI: 10.3233/CBM-130310]

30 Reynés G, Vila V, Martín M, Parada A, Fetcas T, Reganoon E, Martinez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011; 102: 35-41 [PMID: 21607353 DOI: 10.1007/s11060-010-0290-x]

31 Dourouchi M, Pshe ZG, Maleckzadeh M, Golmohaghdam M, Taghipour M, Ghaderi A. Elevated serum IL-17A but not IL-17F in gliomas compared to normal brain. World J Oncol 2018; 14: e218-e228 [PMID: 32639322 DOI: 10.1016/j.wjco.2018.07.003]

32 Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-e228 [PMID: 23639322 DOI: 10.1016/S1470-2045(12)70582-X]

33 Fuji N, Masuoka S, Shikano K, Kusunoki N, Nanki T, Kawai S. Apparent Hypothalamic-Pituitary-Adrenal Axis Suppression via Reduction of Interleukin-6 by Glucocorticoid Therapy in Systemic Immune Diseases. PLoS One 2016; 11: e0167854 [DOI: 10.1371/journal.pone.0167854]

34 Holdhoff M, Yovino SG, Boadu O, Grossman SA. Blood-based biomarkers for malignant gliomas. J Neurooncol 2013;
35 He J, Jiang Y, Liu L, Zuo Z, Zeng C. Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis. *Front Neurol* 2020; **11**: 610163 [PMID: 25862748 DOI: 10.1038/theoncologist.2014-0266]

36 Müllner Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. *Br J Cancer* 2020; **122**: 295-305 [PMID: 21666668 DOI: 10.1038/s41416-019-0603-3]

37 Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. *Oncologist* 2016; **21**: 214-219 [PMID: 26834160 DOI: 10.1634/theoncologist.2015-0342]

38 Lombardi G, Corona G, Bella L, Della Puppa A, Pambuku A, Bertorelle R, Gardiman MP, D’Avella D, Toffoli G, Zagonel V. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. *Oncologist* 2015; **20**: 562-567 [PMID: 25862748 DOI: 10.1038/theoncologist.2014-0266]

39 Choi C, Ganji SK, DeBerardinis RJ, Hatanpää KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pambuku A, Malloy CR, Bachoo RM, Maher EA. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 2012; **18**: 624-629 [PMID: 22281806 DOI: 10.1038/nm.2682]

40 Zachariah MA, Oliveira-Costa JP, Carter BS, Stott SL, Nahed BV. Blood-based biomarkers for the diagnosis and monitoring of gliomas. *Neuro Oncol* 2018; **20**: 1155-1161 [PMID: 29746665 DOI: 10.1093/neuonc/noy074]

41 Yoritsune E, Furuse M, Kawanaka T, Miyata T, Nonoguchi N, Kawabata S, Hayasaki H, Kuroiwa T, Ono K, Shibayama Y, Miyatake S. Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis. *J Radiat Res* 2014; **55**: 803-811 [PMID: 24676944 DOI: 10.1093/jrr/rru017]

42 Sultana N, Sun C, Katsube T, Wang B. Biomarkers of Brain Damage Induced by Radiotherapy. *Dose Response* 2020; **18**: 1559325820938279 [PMID: 32694960 DOI: 10.1177/1559325820938279]

43 Westphal M, Lamszus K. Circulating biomarkers for gliomas. *Nat Rev Neurol* 2015; **11**: 556-566 [PMID: 26369507 DOI: 10.1038/nrneurol.2015.171]

44 De Boeck A, Ahn BY, D’Mello C, Lun X, Menon SV, Alshehri MM, Szulawsky F, Shen Y, Khan L, Dang NH, Reichardt E, Goring KA, King J, Grisdale CJ, Grinshtein N, Hubbardzumyan D, Reilly KM, Blough MD, Cairncross JG, Yong VW, Marra MA, Jones SJM, Kaplan DR, McCoy KD, Holland EC, Bose P, Chan JA, Robbins SM, Senger DL. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. *Nat Commun* 2020; **11**: 4997 [PMID: 33020472 DOI: 10.1038/s41467-020-18569-4]

45 Zhang J, Wang P, Ji W, Ding Y, Lu X. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. *Int J Neurosci* 2017; **127**: 210-217 [PMID: 27050560 DOI: 10.1080/00207454.2015.1175441]

46 Gramatzki D, Frei K, Cathomas G, Moch H, Weller M, Mertz KD. Interleukin-33 in human gliomas: Expression and prognostic significance. *Oncol Lett* 2016; **12**: 445-452 [PMID: 27347163 DOI: 10.3892/ol.2016.4626]
